NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Originally posted here:
Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million

See the original post:
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

See the original post here:
MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results

DEINOVE strengthens its Business development team to deploy its partnering strategy

Read more:
DEINOVE strengthens its Business development team to deploy its partnering strategy

** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**

Read the original:
Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million

GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies to assess the company’s operational performance, including areas related to portfolio valuation, milestone decision making and prioritization. She will report directly to Stanley C. Erck, President and Chief Executive Officer.

See original here:
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management

Company announcement – No. 1 / 2021

Read the original post:
Zealand Pharma announces update to 2020 financial guidance

Read more here:
Blood Sugar Premier – Does This Supplement Really Works? Ingredients & Blood Sugar Premier Reviews by Nuvectramedical

Read more here:
Bespoke Extracts Announces $100K Investment From CEO and Addition of New Brand Ambassador, UFC Fighter Maryna Moroz

Immutep’s Collaboration and Exclusive License with GSK Remains in Place Immutep’s Collaboration and Exclusive License with GSK Remains in Place

See the original post here:
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

Read more from the original source:
MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT®) as a treatment consideration to further lower atherosclerotic cardiovascular disease (ASCVD) in the appropriate patient population.”1

See the original post here:
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases

Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that four abstracts related to its K-NK-cell therapy platform were accepted for presentation at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), which is being held virtually from February 8–12, 2021.

View post:
Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation...

Highlights

Original post:
Immutep Quarterly Activities Report

Original post:
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in...

Go here to see the original:
Nicox Analyst Coverage Initiated by Edison Investment Research

Continued here:
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event.

Read the original here:
PCI Biotech to present at RNA Therapeutics Virtual Conference

DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).

Visit link:
Mydecine Innovations Group Included in First-Ever Psychedelics ETF

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Read the original here:
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT...